Compare S&P500 ETF (SPY) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
S&P500 ETF vs TransMedics Group Inc — how do they compare? S&P500 ETF trades at $772.34, while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: S&P500 ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| SPY | TMDX | |
|---|---|---|
52-Week High | $773.22 | $150.42 |
52-Week Low | $631.99 | $61.99 |
Market Cap | — | $3.10B |
Sector | — | Technology |
Enterprise Value | — | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPY, the SPDR S&P 500 ETF Trust, trades at $772.47, down 0.08% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The ETF's valuation metrics are not applicable as it tracks the S&P 500 index, and it announced a $1.90 dividend payable in July 2026. Recent news highlights the S&P 500 reaching record highs amid mixed sentiment, with some analysts cautioning on high valuations while others project further gains.
The outlook for SPY is cautiously optimistic, driven by strong market momentum and corporate earnings, but faces risks from elevated valuations and potential inflation pressures. Investment opportunity lies in broad U.S. equity exposure, while key risks include market volatility and economic data surprises.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
